Zymeworks re­moves CFO; Gilead ex­tends Nurix deal

Plus, news about On­cono­va Ther­a­peu­tics, Trawsfyny­dd Ther­a­peu­tics, No­cion Ther­a­peu­tics, Gink­go Bioworks and Mod­u­lus Ther­a­peu­tics:

Zymeworks ousts CFO: The biotech dis­closed Mon­day that it had re­moved CFO Christo­pher As­tle on March 31, though did not pro­vide a rea­son in an SEC fil­ing. Pres­i­dent and CEO Ken­neth Gal­braith is serv­ing as in­ter­im CFO un­til the com­pa­ny finds a re­place­ment. “Fol­low­ing care­ful con­sid­er­a­tion, and in the in­ter­est of our com­mit­ment to con­tin­u­ing our growth and suc­cess, the de­ci­sion was made to ini­ti­ate a search for a new CFO who pos­sess­es the spe­cif­ic ex­pe­ri­ence, ex­per­tise and vi­sion to dri­ve our busi­ness strate­gies for­ward ef­fec­tive­ly,” a spokesper­son wrote to End­points in an email. The com­pa­ny’s shares $ZYME fell about 4% on Tues­day. — Lei Lei Wu

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.